Reports Of Autopsies In VAERS And Associated Adverse Events Linked To Cause Of Death
Authors: Rose Jessica 
Published: July 2024

Background: Since the roll-out of the Pfizer-BioNTech BNT162b2, Moderna mRNA-1273, Janssen Ad26.COV2.S and Novavax COVID-19 injections in the United States, millions of individuals have reported adverse events (AEs) using the Vaccine Adverse Events Reports System (VAERS).Objectives: To examine reports of death in VAERS associated with autopsy reports in the context of the COVID-19 injectable products and Influenza vaccines for equivalent timeframes.Methods: VAERS data was used to examine the frequency of reporting of general AES, and specific AEs linked to autopsy reports since the beginning of the COVID-19 mass injection campaign - up to and including July 2024. COVID-19 injectable product AE data collected from 2021-2023, were compared to Influenza vaccine AE data collected from 2018-2020, thus matching timeframes of administration and VAERS reporting of AEs associated with each product. The total number of shots administered per product type was also calculated and used to calculate rates of AEs per million doses. Autopsy reports made in association with the COVID-19 injectable products were also further examined in the context of fetal and child deaths. In addition geographic locations were mapped according to ratios of autopsies to deaths per state in order to visualize which states ordered the most autopsies.Results: The number of autopsy reports in VAERS domestic data following COVID-19 injection spanning 2021-2023 is 18 times higher than the average of Influenza vaccines for the timeframe spanning 2018-2020. This represents a 1,714% increase in absolute number of reports of autopsy for equal timeframes in the context of four COVID-19 products versus twelve Influenza vaccines. The average age of the reports involving autopsy in the COVID-19 shot context is 53 whereas it is 25 in the Influenza shot context. 69% of all COVID-19 shot autopsy-linked reports were associated with cardiovascular AEs, and more precisely, 11%, 12% and 16% of these reports are associated with myocarditis, cardiac arrest and pulmonary embolism (PE), respectively. Likewise for Influenza autopsy-linked reports with regard to percentage of autopsy reports associated with cardiovascular issues (67% of total), but only with 7% associated with myocarditis; there were no autopsy reports involving cardiac arrest or pulmonary embolism. The rate of reporting of autopsies in the COVID-19 shot context decreased significantly (p = 0.03) by a staggering 77.6% when compared to the Influenza shot context indicating a questionable discrepancy between standard autopsy request rates and rates in the COVID-19 era.Conclusions: Statistically, there is a significant difference between the rate of autopsy reporting when comparing Influenza vaccines to COVID-19 injectable products with. Despite the fact that there is a 1,714% increase in absolute count of autopsies in VAERS when comparing Influenza vaccine to COVID-19 injectable product reports, there is a 77.6% decrease in the rate of autopsy reporting in the context of deaths. 69% (N=262) of autopsy-linked VAERS reports in the context of COVID-19 injections involve cardiovascular AEs including myocarditis, cardiac arrest and PE and supports the theory that the COVID-19 injectable products are deterministic for myocarditis, cardiac arrest and PE. Noteworthy, is that 67% (N=14) of autopsy-linked VAERS reports in the context of Influenza vaccines involve cardiovascular-related death, but with no reported involvement of cardiac arrest or PE.